443 related articles for article (PubMed ID: 32788708)
1. The type I interferon response in COVID-19: implications for treatment.
Lee JS; Shin EC
Nat Rev Immunol; 2020 Oct; 20(10):585-586. PubMed ID: 32788708
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
4. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Spinelli FR; Conti F; Gadina M
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
[TBL] [Abstract][Full Text] [Related]
5. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
6. What is the role of rheumatologists in the era of COVID-19?
Marotto D; Sarzi-Puttini P
Autoimmun Rev; 2020 Jun; 19(6):102539. PubMed ID: 32251716
[No Abstract] [Full Text] [Related]
7. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
[No Abstract] [Full Text] [Related]
8. Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Laforge M; Elbim C; Frère C; Hémadi M; Massaad C; Nuss P; Benoliel JJ; Becker C
Nat Rev Immunol; 2020 Sep; 20(9):515-516. PubMed ID: 32728221
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 herd immunity: where are we?
Fontanet A; Cauchemez S
Nat Rev Immunol; 2020 Oct; 20(10):583-584. PubMed ID: 32908300
[TBL] [Abstract][Full Text] [Related]
12. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
13. [Not Available].
Balavoine JF
Rev Med Suisse; 2020 May; 16(695):1126. PubMed ID: 32462848
[No Abstract] [Full Text] [Related]
14. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
Ledford H
Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
[No Abstract] [Full Text] [Related]
15. Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on.
Lipworth B; Chan R; Kuo CR
Ann Allergy Asthma Immunol; 2020 Nov; 125(5):503-504. PubMed ID: 32585180
[No Abstract] [Full Text] [Related]
16. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
17. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
18. Not just antibodies: B cells and T cells mediate immunity to COVID-19.
Cox RJ; Brokstad KA
Nat Rev Immunol; 2020 Oct; 20(10):581-582. PubMed ID: 32839569
[TBL] [Abstract][Full Text] [Related]
19. After 62 years of regulating immunity, dexamethasone meets COVID-19.
Cain DW; Cidlowski JA
Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
[TBL] [Abstract][Full Text] [Related]
20. Immune status could determine efficacy of COVID-19 therapies.
Cully M
Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
[No Abstract] [Full Text] [Related]
[Next] [New Search]